Moderna and Merck announced that a phase 3 trial of their personalized mRNA cancer therapy, intismeran, given with Keytruda (pembrolizumab), met two key endpoints in people with high‑risk, resected melanoma. The combination reduced the risk of recurrence or death (recurrence‑free survival) and improved distant metastasis‑free survival, a measure of time before cancer spreads to another part of the body or death.
Detailed efficacy and safety results from the phase 3 study have not yet been released. The companies said they plan to submit the data to regulatory authorities and present full results at a forthcoming medical meeting. Intismeran remains investigational and is not approved by the U.S. Food and Drug Administration.
Intismeran is a custom‑made mRNA vaccine manufactured for each patient. It encodes up to 34 patient‑specific neoantigens — new proteins produced when tumor DNA mutates, identified by sequencing a person’s tumor. The vaccine is designed to prime the immune system by training T cells to recognize those neoantigens. Keytruda is a PD‑1 checkpoint inhibitor that helps unleash immune responses against cancer. Combined, the vaccine gives the immune system specific directions to find cancer while Keytruda removes brakes on the immune response.
Earlier phase 2b results reported that intismeran plus Keytruda was associated with a 49% lower risk of melanoma recurrence or death and a 59% lower risk of distant metastasis or death compared with Keytruda alone. The phase 3 results are the first to show benefit in a large randomized setting for this personalized neoantigen vaccine approach in the adjuvant melanoma setting.
Clinical leaders described the announcement as encouraging. The trial’s principal investigator noted the finding is an important step for adjuvant melanoma treatment, highlighting the potential of a therapy tailored to each tumor’s mutational “fingerprint.” Executives from the companies framed the results as reinforcing the promise of more personalized cancer immunotherapy.
Independent oncology experts urge caution until the full data are available. Key questions include the magnitude and durability of benefit beyond statistical significance, and a clear picture of safety. Immune‑based therapies can cause immune‑related adverse events — inflammation or autoimmune reactions affecting normal tissues — and it’s important to know whether adding an individualized neoantigen vaccine changes the frequency or severity of these toxicities or introduces new complications.
The phase 3 trial is ongoing. If detailed results continue to support benefit with an acceptable safety profile, personalized mRNA vaccines like intismeran could become a new option in melanoma adjuvant therapy. For now, clinicians and patients will await the full dataset to understand the balance of benefit and risk.
